Literature DB >> 12101259

Viral chemokine-binding proteins.

Bruce T Seet1, Grant McFadden.   

Abstract

The chemokines are a large family of small signaling proteins that bind to G-protein-coupled receptors (GPCRs) on target cells and mediate the directional migration of immune cells into sites of infection or inflammation. The large DNA viruses, particularly the poxviruses and herpesviruses, have evolved several mechanisms to corrupt the normal functioning of the chemokine network. Two strategies rely on mimicking chemokines or chemokine receptors. A third strategy involves the production of secreted chemokine-binding proteins (CKBPs) that exhibit no sequence similarity to any known host proteins, yet function to competitively bind and inhibit the interactions of chemokines with cognate receptors. Each strategy has provided unique insights into the elusively complex world of the chemokines. Here, we focus on recent advances made in the understanding of secreted CKBPs encoded by poxviruses and herpesviruses. A better understanding of how viral CKBPs function to manipulate the immune response may provide further clues as to how to develop specific therapeutic agents to abrogate chemokine-mediated disease conditions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12101259

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  34 in total

1.  Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS.

Authors:  Susana Guerra; José Manuel González; Núria Climent; Hugh Reyburn; Luis A López-Fernández; José L Nájera; Carmen E Gómez; Felipe García; José M Gatell; Teresa Gallart; Mariano Esteban
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

Review 2.  Poxvirus immunomodulatory strategies: current perspectives.

Authors:  J B Johnston; Grant McFadden
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

Review 3.  [Chemokine--possible new options for the treatment of multiple sclerosis].

Authors:  C Trebst; R M Ransohoff; A Windhagen; M Stangel
Journal:  Nervenarzt       Date:  2003-10       Impact factor: 1.214

Review 4.  Immune evasion by Kaposi's sarcoma-associated herpesvirus.

Authors:  Hye-Ra Lee; Stacy Lee; Preet M Chaudhary; Parkash Gill; Jae U Jung
Journal:  Future Microbiol       Date:  2010-09       Impact factor: 3.165

5.  Upon viral exposure, myeloid and plasmacytoid dendritic cells produce 3 waves of distinct chemokines to recruit immune effectors.

Authors:  Bernard Piqueras; John Connolly; Heidi Freitas; Anna Karolina Palucka; Jacques Banchereau
Journal:  Blood       Date:  2005-11-29       Impact factor: 22.113

6.  Vaccinia virus activation of CCR5 invokes tyrosine phosphorylation signaling events that support virus replication.

Authors:  Ramtin Rahbar; Thomas T Murooka; Anna A Hinek; Carole L Galligan; Antonella Sassano; Celeste Yu; Kishore Srivastava; Leonidas C Platanias; Eleanor N Fish
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

7.  Human cytomegalovirus immediate-early 2 protein IE86 blocks virus-induced chemokine expression.

Authors:  R Travis Taylor; Wade A Bresnahan
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

8.  Role for CCR5 in dissemination of vaccinia virus in vivo.

Authors:  Ramtin Rahbar; Thomas T Murooka; Eleanor N Fish
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

9.  rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy.

Authors:  Lan Wu; Tian-gui Huang; Marcia Meseck; Jennifer Altomonte; Oliver Ebert; Katsunori Shinozaki; Adolfo García-Sastre; John Fallon; John Mandeli; Savio L C Woo
Journal:  Hum Gene Ther       Date:  2008-06       Impact factor: 5.695

10.  Analysis of an orf virus chemokine-binding protein: Shifting ligand specificities among a family of poxvirus viroceptors.

Authors:  Bruce T Seet; Catherine A McCaughan; Tracy M Handel; Andrew Mercer; Craig Brunetti; Grant McFadden; Stephen B Fleming
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.